Neoadjuvant Chemotherapy for Resectable Cancer of the Pancreatic Head

• Status: Completed
• Trial end date: 2007-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Neodajuvant chemotherapy with gemcitabine / cisplatin is applied to patients with resectable cancer of pancreatic head.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Zurich
• Treatments: Cisplatin; Gemcitabine

Criteria

Inclusion criteria: - Age > 18 years

• Histologically or cytologically confirmed resectable ductal adenocarcinoma of the pancreatic head

• WHO-performance status 0-2

• Written informed consent

• Discussion in an intrdisciplinary conference

Exclusion criteria: - Insufficient renal function (calculated creatinin clearance < 60ml(min)

• Insufficient hematologic function (neutrophil count <1'000/ul, platelets < 100'000/ul)

• Uncorrectable coagulopathy

• Severe cholestasis (bilirubin >100mmol/l)

• Distant metastases in liver, lungs or other organs

• Peritoneal carcinomatosis

• Unresectable tumor (s. 4.2.)

• Contraindication for Whipple procedure

• Uncontrolled infection

• Neurotphil count > °2

• Estimated life experience < 6 months

• HIV Infection

• Severe medical or psychatric comorbidities which interefere with the participation in this trial or the informed consent

• Female patients in child-bearing age without adequate contraception